LISA-TRACKER Trastuzumab

LISA-TRACKER Trastuzumab is an enzyme linked immunoassay (ELISA) for the quantitative determination of Trastuzumab (anti-HER2) in human serum samples.

Trastuzumab is a humanised monoclonal antibody that reduces cell proliferation by inhibiting Human Epidermal growth factor Receptor-2 (HER2). It is indicated for the treatment of metastatic breast gastric cancers which typically over-express HER2.  It functions to prevent the action of the HER2 which is responsible for the cell proliferation.  During the treatment, some patients can develop antibodies against Trastuzumab.

• Baselga J et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.  Clin. Oncol., 1996, 14, p.737-744.
• Baselga J et al. Pertuzumab plus Trastuzumab plus Docetaxel for metastatic Breast Cancer.  The New England Journal of Medicine, 2012, 366, p.109-119.
• Boekhout A et al.   Oncologist, 2011, 16, p.800-810.
• Damen C et al. Development and validation of an enzyme-linked immunosorbent assay for the quantification of Trastuzumab in human serum and plasma.  Analytical Biochemistry, 2009, 391, p.114-120.
• Goldenberg MM et al. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.  Ther., 1999, 21, p.309-318.
• Jamieson D et al. Development and validation of cell-based ELISA for the quantification of Trastuzumab in human plasma.  Journal of immunological methods, 2009, 345, p. 106-111.
• Levêque D et al. Clinical Pharmacology of Trastuzumab.  Current clinical Pharmacology, 2008, 3, 51-55.
• Maple L et al. Development and validation of ELISA for Herceptin detection in human serum.  Journal of immunological methods, 2004, 295, p. 169-182.
• Molina MA et al. Trastuzumab (Herceptin), a humanized Anti-HER2 Receptor Monoclonal Antibody, Inhibits Basal and Activated HER2 Ectodomain Cleavage in Breast Cancer Cells.  Cancer Research , 2001, 61, p. 4744-4749.
• Pegram MD et al. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat., 1998, 52, p.65-77.
• Piketty ML et al. Biotin: an emerging analytical interference. Ann Biol Clin2017 ; 75(4) : 366-8.
• Sarup JC et al. Characterization of an anti-p185HER2 monoclonal antibody that stimulates receptor function and inhibits tumor cell growth. Growth Reg., 1991, 1, p.72-82.
• Slamon DJ et al. Human Breast Cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 1987, 235, p.177-182.